Rallybio (RLYB) Competitors $0.34 -0.02 (-4.86%) As of 01:35 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. PEPG, AVTX, ARTV, IPSC, MRSN, NRXP, VRCA, PMVP, AKTX, and CNTBShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include PepGen (PEPG), Avalo Therapeutics (AVTX), Artiva Biotherapeutics (ARTV), Century Therapeutics (IPSC), Mersana Therapeutics (MRSN), NRx Pharmaceuticals (NRXP), Verrica Pharmaceuticals (VRCA), PMV Pharmaceuticals (PMVP), Akari Therapeutics (AKTX), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Its Competitors PepGen Avalo Therapeutics Artiva Biotherapeutics Century Therapeutics Mersana Therapeutics NRx Pharmaceuticals Verrica Pharmaceuticals PMV Pharmaceuticals Akari Therapeutics Connect Biopharma Rallybio (NASDAQ:RLYB) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment. Do institutionals and insiders hold more shares of RLYB or PEPG? 90.3% of Rallybio shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 8.7% of Rallybio shares are held by company insiders. Comparatively, 5.2% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate RLYB or PEPG? Rallybio currently has a consensus target price of $10.00, suggesting a potential upside of 2,850.72%. PepGen has a consensus target price of $7.67, suggesting a potential upside of 425.11%. Given Rallybio's higher possible upside, equities research analysts clearly believe Rallybio is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community favor RLYB or PEPG? Rallybio received 22 more outperform votes than PepGen when rated by MarketBeat users. However, 81.48% of users gave PepGen an outperform vote while only 73.33% of users gave Rallybio an outperform vote. CompanyUnderperformOutperformRallybioOutperform Votes4473.33% Underperform Votes1626.67% PepGenOutperform Votes2281.48% Underperform Votes518.52% Is RLYB or PEPG more profitable? PepGen's return on equity of -60.17% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets RallybioN/A -77.39% -69.33% PepGen N/A -60.17%-48.88% Which has preferable earnings & valuation, RLYB or PEPG? Rallybio has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$848K16.63-$74.56M-$1.09-0.31PepGenN/AN/A-$78.63M-$3.13-0.47 Which has more risk and volatility, RLYB or PEPG? Rallybio has a beta of -1.24, meaning that its stock price is 224% less volatile than the S&P 500. Comparatively, PepGen has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Does the media favor RLYB or PEPG? In the previous week, PepGen had 16 more articles in the media than Rallybio. MarketBeat recorded 17 mentions for PepGen and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.89 beat PepGen's score of 0.07 indicating that Rallybio is being referred to more favorably in the media. Company Overall Sentiment Rallybio Very Positive PepGen Neutral SummaryRallybio beats PepGen on 9 of the 16 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.10M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.218.8727.2520.01Price / Sales16.63263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book0.126.617.124.70Net Income-$74.56M$144.20M$3.24B$248.05M7 Day Performance-0.09%3.88%2.75%2.62%1 Month Performance12.63%11.26%9.00%6.32%1 Year Performance-79.46%3.96%31.41%13.78% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio3.2192 of 5 stars$0.34-4.9%$10.00+2,850.7%-78.3%$14.10M$848K-0.2140Positive NewsPEPGPepGen2.7481 of 5 stars$1.44-1.4%$7.67+432.4%-91.9%$47.12MN/A-0.4830Trending NewsGap DownAVTXAvalo Therapeutics3.6048 of 5 stars$4.35+8.8%$30.00+589.7%-57.3%$47.10M$441K0.0040News CoverageShort Interest ↓High Trading VolumeARTVArtiva Biotherapeutics2.618 of 5 stars$1.94+0.5%$19.40+900.0%N/A$47.02M$251K0.0081News CoverageAnalyst UpgradeAnalyst RevisionGap UpIPSCCentury Therapeutics2.5312 of 5 stars$0.54+2.5%$4.20+672.8%-81.4%$46.83M$114.90M-0.29170Gap UpHigh Trading VolumeMRSNMersana Therapeutics4.1147 of 5 stars$0.37+8.8%$5.20+1,290.7%-83.2%$46.60M$34.01M-0.61150NRXPNRx Pharmaceuticals2.1186 of 5 stars$2.68+1.5%$28.50+963.4%+4.8%$46.34MN/A-1.252VRCAVerrica Pharmaceuticals4.4515 of 5 stars$0.54+9.3%$8.00+1,379.6%-93.0%$45.75M$7.18M-0.3040Positive NewsShort Interest ↓PMVPPMV Pharmaceuticals2.4465 of 5 stars$0.88-0.1%$5.50+527.1%-34.7%$45.56MN/A-0.8850Positive NewsAKTXAkari TherapeuticsN/A$1.42+4.8%N/A-61.0%$45.53MN/A0.009Positive NewsGap DownCNTBConnect Biopharma3.6283 of 5 stars$0.82-2.5%$8.00+876.4%-56.0%$45.52M$26.03M0.00110Positive NewsAnalyst Forecast Related Companies and Tools Related Companies PepGen Alternatives Avalo Therapeutics Alternatives Artiva Biotherapeutics Alternatives Century Therapeutics Alternatives Mersana Therapeutics Alternatives NRx Pharmaceuticals Alternatives Verrica Pharmaceuticals Alternatives PMV Pharmaceuticals Alternatives Akari Therapeutics Alternatives Connect Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLYB Stock Free RLYB Stock Alerts